Fauna Bio
Emeryville, US · 6 known investors
Fauna Bio is an AI-driven drug discovery company that studies genetic disease resistance in mammals, using an exclusive biobank of genetic data and its Convergence platform to identify therapeutic targets and develop drugs mimicking natural protective mechanisms. It focuses on conditions such as metabolic disease, obesity resistance, and muscle preservation.
AI & Machine LearningBiotechDeep Tech
Investors · 6
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $550.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $228.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Fauna Bio do?
- Fauna Bio is an AI-driven drug discovery company that studies genetic disease resistance in mammals, using an exclusive biobank of genetic data and its Convergence platform to identify therapeutic targets and develop drugs mimicking natural protective mechanisms. It focuses on conditions such as metabolic disease, obesity resistance, and muscle preservation.
- Who are Fauna Bio's investors?
- Fauna Bio's investors include age1, Farvatn Venture, Lifeforce Capital, Metaplanet, Vibe Capital, Boom Capital Ventures.
- Where is Fauna Bio headquartered?
- Fauna Bio is headquartered in Emeryville, US.